MersV1, Main, Curation, bibRecord, 003A89

Biologically active oligodeoxyribonucleotides. Part 11: The least phosphate-modification of quadruplex-forming hexadeoxyribonucleotide TGGGAG, bearing 3′- and 5′-end-modification, with anti-HIV-1 activity

Identifieur interne : 003A89 ( Main/Curation ); précédent : 003A88; suivant : 003A90

Biologically active oligodeoxyribonucleotides. Part 11: The least phosphate-modification of quadruplex-forming hexadeoxyribonucleotide TGGGAG, bearing 3′- and 5′-end-modification, with anti-HIV-1 activity

Auteurs : Makoto Koizumi [Japon] ; Rika Koga [Japon] ; Hitoshi Hotoda [Japon] ; Toshinori Ohmine [Japon] ; Hidehiko Furukawa [Japon] ; Toshinori Agatsuma [Japon] ; Takashi Nishigaki [Japon] ; Koji Abe [Japon] ; Toshiyuki Kosaka [Japon] ; Shinya Tsutsumi [Japon] ; Junko Sone [Japon] ; Masakatsu Kaneko [Japon] ; Satoshi Kimura [Japon] ; Kaoru Shimada [Japon]

Source :

Bioorganic & Medicinal Chemistry [ 0968-0896 ] ; 1998.

RBID : ISTEX:AFC9863E4C7F650ECA44ED1DCE49EE59F9DF469E

Descripteurs français

English descriptors

KwdEn :
- Anti-HIV Agents (blood), Anti-HIV Agents (chemical synthesis), Anti-HIV Agents (chemistry), Anti-HIV Agents (pharmacology), Base Sequence, Benzyl Compounds, Cell Survival (drug effects), Circular Dichroism, Drug Design, Drug Stability, HIV-1 (drug effects), Humans, Models, Molecular, Molecular Structure, Nucleic Acid Conformation, Oligodeoxyribonucleotides (blood), Oligodeoxyribonucleotides (chemical synthesis), Oligodeoxyribonucleotides (chemistry), Oligodeoxyribonucleotides (pharmacology), Structure-Activity Relationship.
MESH :
- chemical , blood : Anti-HIV Agents, Oligodeoxyribonucleotides.
- chemical , chemical synthesis : Anti-HIV Agents, Oligodeoxyribonucleotides.
- chemical , chemistry : Anti-HIV Agents, Oligodeoxyribonucleotides.
- chemical , pharmacology : Anti-HIV Agents, Oligodeoxyribonucleotides.
- drug effects : Cell Survival, HIV-1.
Teeft :
- Base Sequence, Benzyl Compounds, Calcd, Chem, Circular Dichroism, Drug Design, Drug Stability, Furukawa, High activity, Hotoda, Human plasma, Humans, Kimura, Koizumi, Models, Molecular, Molecular Structure, Negative charges, Nucleic Acid Conformation, Odns, Open circles, Other odns, Oxygen atom, Phase hplc, Pme2, Quadruplex, Quadruplex structure, Reaction mixture, Room temperature, Shimada, Solid circles, Structure-Activity Relationship, Sulfur atom, Tertiary structures.

Abstract

Abstract: We have found that a hexadeoxyribonucleotide (5′TGGGAG3′, R-95288), Koizumi, M. et al. Bioorganic & Medicinal Chemistry, 1997, 5, 2235, bearing a 3,4-dibenzyloxybenzyl (3,4-DBB) group at the 5′-end and a 2-hydroxyethylphosphate at the 3′-end, has high anti-HIV-1 activity and the least cytotoxicity in vitro and in vivo. In order to synthesize more potent hexadeoxyribonucleotides, we substituted phosphodiester (PO) bonds in the 6-mer with the least phosphorothioate (PS), phosphoramidate (PN), or methylphosphonate (PMe) bonds. When more than two PN or PMe bonds were introduced into a 6-mer, the phosphate-modified 6-mers had weak or no anti-HIV-1 activity, in spite of quadruplex structure formation. However, when PS bonds were substituted for PO bonds, anti-HIV-1 activity of their 6-mers did not dramatically decrease, compared with compounds substituted with PN or PMe bonds. The results suggest that the formation of a quadruplex structure is not always sufficient for anti-HIV-1 activity of the 6-mer, and that net negative charges derived from PO or PS bonds in the quadruplex are important for anti-HIV-1 activity. Moreover, among various phosphate-modified ODNs, we found that the anti-HIV-1 activity of ODN PS7 with only one PS bond was the same as that of R-95288, both having a high stability in human plasma.

Graphicgr1

Url:

https://api.istex.fr/ark:/67375/6H6-MD9B78LG-8/fulltext.pdf

DOI: 10.1016/S0968-0896(98)80021-7

Links toward previous steps (curation, corpus...)

to stream Istex, to step Corpus: Pour aller vers cette notice dans l'étape Curation :000114
to stream Istex, to step Curation: Pour aller vers cette notice dans l'étape Curation :000114
to stream Istex, to step Checkpoint: Pour aller vers cette notice dans l'étape Curation :001298
to stream Main, to step Merge: Pour aller vers cette notice dans l'étape Curation :003B38
to stream PubMed, to step Corpus: Pour aller vers cette notice dans l'étape Curation :002649
to stream PubMed, to step Curation: Pour aller vers cette notice dans l'étape Curation :002649
to stream PubMed, to step Checkpoint: Pour aller vers cette notice dans l'étape Curation :002553
to stream Ncbi, to step Merge: Pour aller vers cette notice dans l'étape Curation :002B56
to stream Ncbi, to step Curation: Pour aller vers cette notice dans l'étape Curation :002B56
to stream Ncbi, to step Checkpoint: Pour aller vers cette notice dans l'étape Curation :002B56
to stream Main, to step Merge: Pour aller vers cette notice dans l'étape Curation :003A67

Links to Exploration step

ISTEX:AFC9863E4C7F650ECA44ED1DCE49EE59F9DF469E

Le document en format XML

<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title>Biologically active oligodeoxyribonucleotides. Part 11: The least phosphate-modification of quadruplex-forming hexadeoxyribonucleotide TGGGAG, bearing 3′- and 5′-end-modification, with anti-HIV-1 activity</title>
<author><name sortKey="Koizumi, Makoto" sort="Koizumi, Makoto" uniqKey="Koizumi M" first="Makoto" last="Koizumi">Makoto Koizumi</name>
</author>
<author><name sortKey="Koga, Rika" sort="Koga, Rika" uniqKey="Koga R" first="Rika" last="Koga">Rika Koga</name>
</author>
<author><name sortKey="Hotoda, Hitoshi" sort="Hotoda, Hitoshi" uniqKey="Hotoda H" first="Hitoshi" last="Hotoda">Hitoshi Hotoda</name>
</author>
<author><name sortKey="Ohmine, Toshinori" sort="Ohmine, Toshinori" uniqKey="Ohmine T" first="Toshinori" last="Ohmine">Toshinori Ohmine</name>
</author>
<author><name sortKey="Furukawa, Hidehiko" sort="Furukawa, Hidehiko" uniqKey="Furukawa H" first="Hidehiko" last="Furukawa">Hidehiko Furukawa</name>
</author>
<author><name sortKey="Agatsuma, Toshinori" sort="Agatsuma, Toshinori" uniqKey="Agatsuma T" first="Toshinori" last="Agatsuma">Toshinori Agatsuma</name>
</author>
<author><name sortKey="Nishigaki, Takashi" sort="Nishigaki, Takashi" uniqKey="Nishigaki T" first="Takashi" last="Nishigaki">Takashi Nishigaki</name>
</author>
<author><name sortKey="Abe, Koji" sort="Abe, Koji" uniqKey="Abe K" first="Koji" last="Abe">Koji Abe</name>
</author>
<author><name sortKey="Kosaka, Toshiyuki" sort="Kosaka, Toshiyuki" uniqKey="Kosaka T" first="Toshiyuki" last="Kosaka">Toshiyuki Kosaka</name>
</author>
<author><name sortKey="Tsutsumi, Shinya" sort="Tsutsumi, Shinya" uniqKey="Tsutsumi S" first="Shinya" last="Tsutsumi">Shinya Tsutsumi</name>
</author>
<author><name sortKey="Sone, Junko" sort="Sone, Junko" uniqKey="Sone J" first="Junko" last="Sone">Junko Sone</name>
</author>
<author><name sortKey="Kaneko, Masakatsu" sort="Kaneko, Masakatsu" uniqKey="Kaneko M" first="Masakatsu" last="Kaneko">Masakatsu Kaneko</name>
</author>
<author><name sortKey="Kimura, Satoshi" sort="Kimura, Satoshi" uniqKey="Kimura S" first="Satoshi" last="Kimura">Satoshi Kimura</name>
</author>
<author><name sortKey="Shimada, Kaoru" sort="Shimada, Kaoru" uniqKey="Shimada K" first="Kaoru" last="Shimada">Kaoru Shimada</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">ISTEX</idno>
<idno type="RBID">ISTEX:AFC9863E4C7F650ECA44ED1DCE49EE59F9DF469E</idno>
<date when="1998" year="1998">1998</date>
<idno type="doi">10.1016/S0968-0896(98)80021-7</idno>
<idno type="url">https://api.istex.fr/ark:/67375/6H6-MD9B78LG-8/fulltext.pdf</idno>
<idno type="wicri:Area/Istex/Corpus">000114</idno>
<idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">000114</idno>
<idno type="wicri:Area/Istex/Curation">000114</idno>
<idno type="wicri:Area/Istex/Checkpoint">001298</idno>
<idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Checkpoint">001298</idno>
<idno type="wicri:doubleKey">0968-0896:1998:Koizumi M:biologically:active:oligodeoxyribonucleotides</idno>
<idno type="wicri:Area/Main/Merge">003B38</idno>
<idno type="wicri:source">PubMed</idno>
<idno type="RBID">pubmed:9925303</idno>
<idno type="wicri:Area/PubMed/Corpus">002649</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">002649</idno>
<idno type="wicri:Area/PubMed/Curation">002649</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">002649</idno>
<idno type="wicri:Area/PubMed/Checkpoint">002553</idno>
<idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">002553</idno>
<idno type="wicri:Area/Ncbi/Merge">002B56</idno>
<idno type="wicri:Area/Ncbi/Curation">002B56</idno>
<idno type="wicri:Area/Ncbi/Checkpoint">002B56</idno>
<idno type="wicri:doubleKey">0968-0896:1998:Koizumi M:biologically:active:oligodeoxyribonucleotides</idno>
<idno type="wicri:Area/Main/Merge">003A67</idno>
<idno type="wicri:Area/Main/Curation">003A89</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title level="a">Biologically active oligodeoxyribonucleotides. Part 11: The least phosphate-modification of quadruplex-forming hexadeoxyribonucleotide TGGGAG, bearing 3′- and 5′-end-modification, with anti-HIV-1 activity</title>
<author><name sortKey="Koizumi, Makoto" sort="Koizumi, Makoto" uniqKey="Koizumi M" first="Makoto" last="Koizumi">Makoto Koizumi</name>
<affiliation wicri:level="1"><country wicri:rule="url">Japon</country>
</affiliation>
<affiliation wicri:level="1"><country xml:lang="fr">Japon</country>
<wicri:regionArea>Exploratory Chemistry Research Lab., Sankyo Co., Ltd, Tokyo 140</wicri:regionArea>
<placeName><settlement type="city">Tokyo</settlement>
<region type="région">Région de Kantō</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Koga, Rika" sort="Koga, Rika" uniqKey="Koga R" first="Rika" last="Koga">Rika Koga</name>
<affiliation wicri:level="1"><country xml:lang="fr">Japon</country>
<wicri:regionArea>Exploratory Chemistry Research Lab., Sankyo Co., Ltd, Tokyo 140</wicri:regionArea>
<placeName><settlement type="city">Tokyo</settlement>
<region type="région">Région de Kantō</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Hotoda, Hitoshi" sort="Hotoda, Hitoshi" uniqKey="Hotoda H" first="Hitoshi" last="Hotoda">Hitoshi Hotoda</name>
<affiliation wicri:level="1"><country xml:lang="fr">Japon</country>
<wicri:regionArea>Exploratory Chemistry Research Lab., Sankyo Co., Ltd, Tokyo 140</wicri:regionArea>
<placeName><settlement type="city">Tokyo</settlement>
<region type="région">Région de Kantō</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Ohmine, Toshinori" sort="Ohmine, Toshinori" uniqKey="Ohmine T" first="Toshinori" last="Ohmine">Toshinori Ohmine</name>
<affiliation wicri:level="1"><country xml:lang="fr">Japon</country>
<wicri:regionArea>Biological Research Lab., Sankyo Co., Ltd, Tokyo 140</wicri:regionArea>
<placeName><settlement type="city">Tokyo</settlement>
<region type="région">Région de Kantō</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Furukawa, Hidehiko" sort="Furukawa, Hidehiko" uniqKey="Furukawa H" first="Hidehiko" last="Furukawa">Hidehiko Furukawa</name>
<affiliation wicri:level="1"><country xml:lang="fr">Japon</country>
<wicri:regionArea>Biological Research Lab., Sankyo Co., Ltd, Tokyo 140</wicri:regionArea>
<placeName><settlement type="city">Tokyo</settlement>
<region type="région">Région de Kantō</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Agatsuma, Toshinori" sort="Agatsuma, Toshinori" uniqKey="Agatsuma T" first="Toshinori" last="Agatsuma">Toshinori Agatsuma</name>
<affiliation wicri:level="1"><country xml:lang="fr">Japon</country>
<wicri:regionArea>Biological Research Lab., Sankyo Co., Ltd, Tokyo 140</wicri:regionArea>
<placeName><settlement type="city">Tokyo</settlement>
<region type="région">Région de Kantō</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Nishigaki, Takashi" sort="Nishigaki, Takashi" uniqKey="Nishigaki T" first="Takashi" last="Nishigaki">Takashi Nishigaki</name>
<affiliation wicri:level="1"><country xml:lang="fr">Japon</country>
<wicri:regionArea>Biological Research Lab., Sankyo Co., Ltd, Tokyo 140</wicri:regionArea>
<placeName><settlement type="city">Tokyo</settlement>
<region type="région">Région de Kantō</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Abe, Koji" sort="Abe, Koji" uniqKey="Abe K" first="Koji" last="Abe">Koji Abe</name>
<affiliation wicri:level="1"><country xml:lang="fr">Japon</country>
<wicri:regionArea>Analytical and Metabolic Research Lab., Sankyo Co., Ltd, Tokyo 140</wicri:regionArea>
<placeName><settlement type="city">Tokyo</settlement>
<region type="région">Région de Kantō</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Kosaka, Toshiyuki" sort="Kosaka, Toshiyuki" uniqKey="Kosaka T" first="Toshiyuki" last="Kosaka">Toshiyuki Kosaka</name>
<affiliation wicri:level="1"><country xml:lang="fr">Japon</country>
<wicri:regionArea>Analytical and Metabolic Research Lab., Sankyo Co., Ltd, Tokyo 140</wicri:regionArea>
<placeName><settlement type="city">Tokyo</settlement>
<region type="région">Région de Kantō</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Tsutsumi, Shinya" sort="Tsutsumi, Shinya" uniqKey="Tsutsumi S" first="Shinya" last="Tsutsumi">Shinya Tsutsumi</name>
<affiliation wicri:level="1"><country xml:lang="fr">Japon</country>
<wicri:regionArea>Analytical and Metabolic Research Lab., Sankyo Co., Ltd, Tokyo 140</wicri:regionArea>
<placeName><settlement type="city">Tokyo</settlement>
<region type="région">Région de Kantō</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Sone, Junko" sort="Sone, Junko" uniqKey="Sone J" first="Junko" last="Sone">Junko Sone</name>
<affiliation wicri:level="1"><country xml:lang="fr">Japon</country>
<wicri:regionArea>Analytical and Metabolic Research Lab., Sankyo Co., Ltd, Tokyo 140</wicri:regionArea>
<placeName><settlement type="city">Tokyo</settlement>
<region type="région">Région de Kantō</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Kaneko, Masakatsu" sort="Kaneko, Masakatsu" uniqKey="Kaneko M" first="Masakatsu" last="Kaneko">Masakatsu Kaneko</name>
<affiliation wicri:level="1"><country xml:lang="fr">Japon</country>
<wicri:regionArea>Exploratory Chemistry Research Lab., Sankyo Co., Ltd, Tokyo 140</wicri:regionArea>
<placeName><settlement type="city">Tokyo</settlement>
<region type="région">Région de Kantō</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Kimura, Satoshi" sort="Kimura, Satoshi" uniqKey="Kimura S" first="Satoshi" last="Kimura">Satoshi Kimura</name>
<affiliation wicri:level="4"><country xml:lang="fr">Japon</country>
<wicri:regionArea>Department of Infectious Diseases, Institute of Medical Science, University of Tokyo, Tokyo 108</wicri:regionArea>
<placeName><settlement type="city">Tokyo</settlement>
<region type="région">Région de Kantō</region>
</placeName>
<orgName type="university">Université de Tokyo</orgName>
<placeName><settlement type="city">Tokyo</settlement>
<region type="province">Région de Kantō</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Shimada, Kaoru" sort="Shimada, Kaoru" uniqKey="Shimada K" first="Kaoru" last="Shimada">Kaoru Shimada</name>
<affiliation wicri:level="4"><country xml:lang="fr">Japon</country>
<wicri:regionArea>Department of Infectious Diseases, Institute of Medical Science, University of Tokyo, Tokyo 108</wicri:regionArea>
<placeName><settlement type="city">Tokyo</settlement>
<region type="région">Région de Kantō</region>
</placeName>
<orgName type="university">Université de Tokyo</orgName>
<placeName><settlement type="city">Tokyo</settlement>
<region type="province">Région de Kantō</region>
</placeName>
</affiliation>
</author>
</analytic>
<monogr></monogr>
<series><title level="j">Bioorganic & Medicinal Chemistry</title>
<title level="j" type="abbrev">BMC</title>
<idno type="ISSN">0968-0896</idno>
<imprint><publisher>ELSEVIER</publisher>
<date type="published" when="1998">1998</date>
<biblScope unit="volume">6</biblScope>
<biblScope unit="issue">12</biblScope>
<biblScope unit="page" from="2469">2469</biblScope>
<biblScope unit="page" to="2475">2475</biblScope>
</imprint>
<idno type="ISSN">0968-0896</idno>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><idno type="ISSN">0968-0896</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Anti-HIV Agents (blood)</term>
<term>Anti-HIV Agents (chemical synthesis)</term>
<term>Anti-HIV Agents (chemistry)</term>
<term>Anti-HIV Agents (pharmacology)</term>
<term>Base Sequence</term>
<term>Benzyl Compounds</term>
<term>Cell Survival (drug effects)</term>
<term>Circular Dichroism</term>
<term>Drug Design</term>
<term>Drug Stability</term>
<term>HIV-1 (drug effects)</term>
<term>Humans</term>
<term>Models, Molecular</term>
<term>Molecular Structure</term>
<term>Nucleic Acid Conformation</term>
<term>Oligodeoxyribonucleotides (blood)</term>
<term>Oligodeoxyribonucleotides (chemical synthesis)</term>
<term>Oligodeoxyribonucleotides (chemistry)</term>
<term>Oligodeoxyribonucleotides (pharmacology)</term>
<term>Structure-Activity Relationship</term>
</keywords>
<keywords scheme="KwdFr" xml:lang="fr"><term>Agents antiVIH ()</term>
<term>Agents antiVIH (pharmacologie)</term>
<term>Agents antiVIH (sang)</term>
<term>Agents antiVIH (synthèse chimique)</term>
<term>Composés benzyliques</term>
<term>Conception de médicament</term>
<term>Conformation d'acide nucléique</term>
<term>Dichroïsme circulaire</term>
<term>Humains</term>
<term>Modèles moléculaires</term>
<term>Oligodésoxyribonucléotides ()</term>
<term>Oligodésoxyribonucléotides (pharmacologie)</term>
<term>Oligodésoxyribonucléotides (sang)</term>
<term>Oligodésoxyribonucléotides (synthèse chimique)</term>
<term>Relation structure-activité</term>
<term>Stabilité de médicament</term>
<term>Structure moléculaire</term>
<term>Survie cellulaire ()</term>
<term>Séquence nucléotidique</term>
<term>VIH-1 (Virus de l'Immunodéficience Humaine de type 1) ()</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="blood" xml:lang="en"><term>Anti-HIV Agents</term>
<term>Oligodeoxyribonucleotides</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="chemical synthesis" xml:lang="en"><term>Anti-HIV Agents</term>
<term>Oligodeoxyribonucleotides</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="chemistry" xml:lang="en"><term>Anti-HIV Agents</term>
<term>Oligodeoxyribonucleotides</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="pharmacology" xml:lang="en"><term>Anti-HIV Agents</term>
<term>Oligodeoxyribonucleotides</term>
</keywords>
<keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Cell Survival</term>
<term>HIV-1</term>
</keywords>
<keywords scheme="MESH" qualifier="pharmacologie" xml:lang="fr"><term>Agents antiVIH</term>
<term>Oligodésoxyribonucléotides</term>
</keywords>
<keywords scheme="MESH" qualifier="sang" xml:lang="fr"><term>Agents antiVIH</term>
<term>Oligodésoxyribonucléotides</term>
</keywords>
<keywords scheme="MESH" qualifier="synthèse chimique" xml:lang="fr"><term>Agents antiVIH</term>
<term>Oligodésoxyribonucléotides</term>
</keywords>
<keywords scheme="Teeft" xml:lang="en"><term>Base Sequence</term>
<term>Benzyl Compounds</term>
<term>Calcd</term>
<term>Chem</term>
<term>Circular Dichroism</term>
<term>Drug Design</term>
<term>Drug Stability</term>
<term>Furukawa</term>
<term>High activity</term>
<term>Hotoda</term>
<term>Human plasma</term>
<term>Humans</term>
<term>Kimura</term>
<term>Koizumi</term>
<term>Models, Molecular</term>
<term>Molecular Structure</term>
<term>Negative charges</term>
<term>Nucleic Acid Conformation</term>
<term>Odns</term>
<term>Open circles</term>
<term>Other odns</term>
<term>Oxygen atom</term>
<term>Phase hplc</term>
<term>Pme2</term>
<term>Quadruplex</term>
<term>Quadruplex structure</term>
<term>Reaction mixture</term>
<term>Room temperature</term>
<term>Shimada</term>
<term>Solid circles</term>
<term>Structure-Activity Relationship</term>
<term>Sulfur atom</term>
<term>Tertiary structures</term>
</keywords>
<keywords scheme="MESH" xml:lang="fr"><term>Agents antiVIH</term>
<term>Composés benzyliques</term>
<term>Conception de médicament</term>
<term>Conformation d'acide nucléique</term>
<term>Dichroïsme circulaire</term>
<term>Humains</term>
<term>Modèles moléculaires</term>
<term>Oligodésoxyribonucléotides</term>
<term>Relation structure-activité</term>
<term>Stabilité de médicament</term>
<term>Structure moléculaire</term>
<term>Survie cellulaire</term>
<term>Séquence nucléotidique</term>
<term>VIH-1 (Virus de l'Immunodéficience Humaine de type 1)</term>
</keywords>
</textClass>
<langUsage><language ident="en">en</language>
</langUsage>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Abstract: We have found that a hexadeoxyribonucleotide (5′TGGGAG3′, R-95288), Koizumi, M. et al. Bioorganic & Medicinal Chemistry, 1997, 5, 2235, bearing a 3,4-dibenzyloxybenzyl (3,4-DBB) group at the 5′-end and a 2-hydroxyethylphosphate at the 3′-end, has high anti-HIV-1 activity and the least cytotoxicity in vitro and in vivo. In order to synthesize more potent hexadeoxyribonucleotides, we substituted phosphodiester (PO) bonds in the 6-mer with the least phosphorothioate (PS), phosphoramidate (PN), or methylphosphonate (PMe) bonds. When more than two PN or PMe bonds were introduced into a 6-mer, the phosphate-modified 6-mers had weak or no anti-HIV-1 activity, in spite of quadruplex structure formation. However, when PS bonds were substituted for PO bonds, anti-HIV-1 activity of their 6-mers did not dramatically decrease, compared with compounds substituted with PN or PMe bonds. The results suggest that the formation of a quadruplex structure is not always sufficient for anti-HIV-1 activity of the 6-mer, and that net negative charges derived from PO or PS bonds in the quadruplex are important for anti-HIV-1 activity. Moreover, among various phosphate-modified ODNs, we found that the anti-HIV-1 activity of ODN PS7 with only one PS bond was the same as that of R-95288, both having a high stability in human plasma.</div>
<div type="abstract">Graphicgr1 </div>
</front>
</TEI>
<double idat="0968-0896:1998:Koizumi M:biologically:active:oligodeoxyribonucleotides"><ISTEX><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title>Biologically active oligodeoxyribonucleotides. Part 11: The least phosphate-modification of quadruplex-forming hexadeoxyribonucleotide TGGGAG, bearing 3′- and 5′-end-modification, with anti-HIV-1 activity</title>
<author><name sortKey="Koizumi, Makoto" sort="Koizumi, Makoto" uniqKey="Koizumi M" first="Makoto" last="Koizumi">Makoto Koizumi</name>
</author>
<author><name sortKey="Koga, Rika" sort="Koga, Rika" uniqKey="Koga R" first="Rika" last="Koga">Rika Koga</name>
</author>
<author><name sortKey="Hotoda, Hitoshi" sort="Hotoda, Hitoshi" uniqKey="Hotoda H" first="Hitoshi" last="Hotoda">Hitoshi Hotoda</name>
</author>
<author><name sortKey="Ohmine, Toshinori" sort="Ohmine, Toshinori" uniqKey="Ohmine T" first="Toshinori" last="Ohmine">Toshinori Ohmine</name>
</author>
<author><name sortKey="Furukawa, Hidehiko" sort="Furukawa, Hidehiko" uniqKey="Furukawa H" first="Hidehiko" last="Furukawa">Hidehiko Furukawa</name>
</author>
<author><name sortKey="Agatsuma, Toshinori" sort="Agatsuma, Toshinori" uniqKey="Agatsuma T" first="Toshinori" last="Agatsuma">Toshinori Agatsuma</name>
</author>
<author><name sortKey="Nishigaki, Takashi" sort="Nishigaki, Takashi" uniqKey="Nishigaki T" first="Takashi" last="Nishigaki">Takashi Nishigaki</name>
</author>
<author><name sortKey="Abe, Koji" sort="Abe, Koji" uniqKey="Abe K" first="Koji" last="Abe">Koji Abe</name>
</author>
<author><name sortKey="Kosaka, Toshiyuki" sort="Kosaka, Toshiyuki" uniqKey="Kosaka T" first="Toshiyuki" last="Kosaka">Toshiyuki Kosaka</name>
</author>
<author><name sortKey="Tsutsumi, Shinya" sort="Tsutsumi, Shinya" uniqKey="Tsutsumi S" first="Shinya" last="Tsutsumi">Shinya Tsutsumi</name>
</author>
<author><name sortKey="Sone, Junko" sort="Sone, Junko" uniqKey="Sone J" first="Junko" last="Sone">Junko Sone</name>
</author>
<author><name sortKey="Kaneko, Masakatsu" sort="Kaneko, Masakatsu" uniqKey="Kaneko M" first="Masakatsu" last="Kaneko">Masakatsu Kaneko</name>
</author>
<author><name sortKey="Kimura, Satoshi" sort="Kimura, Satoshi" uniqKey="Kimura S" first="Satoshi" last="Kimura">Satoshi Kimura</name>
</author>
<author><name sortKey="Shimada, Kaoru" sort="Shimada, Kaoru" uniqKey="Shimada K" first="Kaoru" last="Shimada">Kaoru Shimada</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">ISTEX</idno>
<idno type="RBID">ISTEX:AFC9863E4C7F650ECA44ED1DCE49EE59F9DF469E</idno>
<date when="1998" year="1998">1998</date>
<idno type="doi">10.1016/S0968-0896(98)80021-7</idno>
<idno type="url">https://api.istex.fr/ark:/67375/6H6-MD9B78LG-8/fulltext.pdf</idno>
<idno type="wicri:Area/Istex/Corpus">000114</idno>
<idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">000114</idno>
<idno type="wicri:Area/Istex/Curation">000114</idno>
<idno type="wicri:Area/Istex/Checkpoint">001298</idno>
<idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Checkpoint">001298</idno>
<idno type="wicri:doubleKey">0968-0896:1998:Koizumi M:biologically:active:oligodeoxyribonucleotides</idno>
<idno type="wicri:Area/Main/Merge">003B38</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title level="a">Biologically active oligodeoxyribonucleotides. Part 11: The least phosphate-modification of quadruplex-forming hexadeoxyribonucleotide TGGGAG, bearing 3′- and 5′-end-modification, with anti-HIV-1 activity</title>
<author><name sortKey="Koizumi, Makoto" sort="Koizumi, Makoto" uniqKey="Koizumi M" first="Makoto" last="Koizumi">Makoto Koizumi</name>
<affiliation wicri:level="1"><country wicri:rule="url">Japon</country>
</affiliation>
<affiliation wicri:level="1"><country xml:lang="fr">Japon</country>
<wicri:regionArea>Exploratory Chemistry Research Lab., Sankyo Co., Ltd, Tokyo 140</wicri:regionArea>
<placeName><settlement type="city">Tokyo</settlement>
<region type="région">Région de Kantō</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Koga, Rika" sort="Koga, Rika" uniqKey="Koga R" first="Rika" last="Koga">Rika Koga</name>
<affiliation wicri:level="1"><country xml:lang="fr">Japon</country>
<wicri:regionArea>Exploratory Chemistry Research Lab., Sankyo Co., Ltd, Tokyo 140</wicri:regionArea>
<placeName><settlement type="city">Tokyo</settlement>
<region type="région">Région de Kantō</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Hotoda, Hitoshi" sort="Hotoda, Hitoshi" uniqKey="Hotoda H" first="Hitoshi" last="Hotoda">Hitoshi Hotoda</name>
<affiliation wicri:level="1"><country xml:lang="fr">Japon</country>
<wicri:regionArea>Exploratory Chemistry Research Lab., Sankyo Co., Ltd, Tokyo 140</wicri:regionArea>
<placeName><settlement type="city">Tokyo</settlement>
<region type="région">Région de Kantō</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Ohmine, Toshinori" sort="Ohmine, Toshinori" uniqKey="Ohmine T" first="Toshinori" last="Ohmine">Toshinori Ohmine</name>
<affiliation wicri:level="1"><country xml:lang="fr">Japon</country>
<wicri:regionArea>Biological Research Lab., Sankyo Co., Ltd, Tokyo 140</wicri:regionArea>
<placeName><settlement type="city">Tokyo</settlement>
<region type="région">Région de Kantō</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Furukawa, Hidehiko" sort="Furukawa, Hidehiko" uniqKey="Furukawa H" first="Hidehiko" last="Furukawa">Hidehiko Furukawa</name>
<affiliation wicri:level="1"><country xml:lang="fr">Japon</country>
<wicri:regionArea>Biological Research Lab., Sankyo Co., Ltd, Tokyo 140</wicri:regionArea>
<placeName><settlement type="city">Tokyo</settlement>
<region type="région">Région de Kantō</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Agatsuma, Toshinori" sort="Agatsuma, Toshinori" uniqKey="Agatsuma T" first="Toshinori" last="Agatsuma">Toshinori Agatsuma</name>
<affiliation wicri:level="1"><country xml:lang="fr">Japon</country>
<wicri:regionArea>Biological Research Lab., Sankyo Co., Ltd, Tokyo 140</wicri:regionArea>
<placeName><settlement type="city">Tokyo</settlement>
<region type="région">Région de Kantō</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Nishigaki, Takashi" sort="Nishigaki, Takashi" uniqKey="Nishigaki T" first="Takashi" last="Nishigaki">Takashi Nishigaki</name>
<affiliation wicri:level="1"><country xml:lang="fr">Japon</country>
<wicri:regionArea>Biological Research Lab., Sankyo Co., Ltd, Tokyo 140</wicri:regionArea>
<placeName><settlement type="city">Tokyo</settlement>
<region type="région">Région de Kantō</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Abe, Koji" sort="Abe, Koji" uniqKey="Abe K" first="Koji" last="Abe">Koji Abe</name>
<affiliation wicri:level="1"><country xml:lang="fr">Japon</country>
<wicri:regionArea>Analytical and Metabolic Research Lab., Sankyo Co., Ltd, Tokyo 140</wicri:regionArea>
<placeName><settlement type="city">Tokyo</settlement>
<region type="région">Région de Kantō</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Kosaka, Toshiyuki" sort="Kosaka, Toshiyuki" uniqKey="Kosaka T" first="Toshiyuki" last="Kosaka">Toshiyuki Kosaka</name>
<affiliation wicri:level="1"><country xml:lang="fr">Japon</country>
<wicri:regionArea>Analytical and Metabolic Research Lab., Sankyo Co., Ltd, Tokyo 140</wicri:regionArea>
<placeName><settlement type="city">Tokyo</settlement>
<region type="région">Région de Kantō</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Tsutsumi, Shinya" sort="Tsutsumi, Shinya" uniqKey="Tsutsumi S" first="Shinya" last="Tsutsumi">Shinya Tsutsumi</name>
<affiliation wicri:level="1"><country xml:lang="fr">Japon</country>
<wicri:regionArea>Analytical and Metabolic Research Lab., Sankyo Co., Ltd, Tokyo 140</wicri:regionArea>
<placeName><settlement type="city">Tokyo</settlement>
<region type="région">Région de Kantō</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Sone, Junko" sort="Sone, Junko" uniqKey="Sone J" first="Junko" last="Sone">Junko Sone</name>
<affiliation wicri:level="1"><country xml:lang="fr">Japon</country>
<wicri:regionArea>Analytical and Metabolic Research Lab., Sankyo Co., Ltd, Tokyo 140</wicri:regionArea>
<placeName><settlement type="city">Tokyo</settlement>
<region type="région">Région de Kantō</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Kaneko, Masakatsu" sort="Kaneko, Masakatsu" uniqKey="Kaneko M" first="Masakatsu" last="Kaneko">Masakatsu Kaneko</name>
<affiliation wicri:level="1"><country xml:lang="fr">Japon</country>
<wicri:regionArea>Exploratory Chemistry Research Lab., Sankyo Co., Ltd, Tokyo 140</wicri:regionArea>
<placeName><settlement type="city">Tokyo</settlement>
<region type="région">Région de Kantō</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Kimura, Satoshi" sort="Kimura, Satoshi" uniqKey="Kimura S" first="Satoshi" last="Kimura">Satoshi Kimura</name>
<affiliation wicri:level="4"><country xml:lang="fr">Japon</country>
<wicri:regionArea>Department of Infectious Diseases, Institute of Medical Science, University of Tokyo, Tokyo 108</wicri:regionArea>
<placeName><settlement type="city">Tokyo</settlement>
<region type="région">Région de Kantō</region>
</placeName>
<orgName type="university">Université de Tokyo</orgName>
<placeName><settlement type="city">Tokyo</settlement>
<region type="province">Région de Kantō</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Shimada, Kaoru" sort="Shimada, Kaoru" uniqKey="Shimada K" first="Kaoru" last="Shimada">Kaoru Shimada</name>
<affiliation wicri:level="4"><country xml:lang="fr">Japon</country>
<wicri:regionArea>Department of Infectious Diseases, Institute of Medical Science, University of Tokyo, Tokyo 108</wicri:regionArea>
<placeName><settlement type="city">Tokyo</settlement>
<region type="région">Région de Kantō</region>
</placeName>
<orgName type="university">Université de Tokyo</orgName>
<placeName><settlement type="city">Tokyo</settlement>
<region type="province">Région de Kantō</region>
</placeName>
</affiliation>
</author>
</analytic>
<monogr></monogr>
<series><title level="j">Bioorganic & Medicinal Chemistry</title>
<title level="j" type="abbrev">BMC</title>
<idno type="ISSN">0968-0896</idno>
<imprint><publisher>ELSEVIER</publisher>
<date type="published" when="1998">1998</date>
<biblScope unit="volume">6</biblScope>
<biblScope unit="issue">12</biblScope>
<biblScope unit="page" from="2469">2469</biblScope>
<biblScope unit="page" to="2475">2475</biblScope>
</imprint>
<idno type="ISSN">0968-0896</idno>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><idno type="ISSN">0968-0896</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="Teeft" xml:lang="en"><term>Calcd</term>
<term>Chem</term>
<term>Furukawa</term>
<term>High activity</term>
<term>Hotoda</term>
<term>Human plasma</term>
<term>Kimura</term>
<term>Koizumi</term>
<term>Negative charges</term>
<term>Odns</term>
<term>Open circles</term>
<term>Other odns</term>
<term>Oxygen atom</term>
<term>Phase hplc</term>
<term>Pme2</term>
<term>Quadruplex</term>
<term>Quadruplex structure</term>
<term>Reaction mixture</term>
<term>Room temperature</term>
<term>Shimada</term>
<term>Solid circles</term>
<term>Sulfur atom</term>
<term>Tertiary structures</term>
</keywords>
</textClass>
<langUsage><language ident="en">en</language>
</langUsage>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Abstract: We have found that a hexadeoxyribonucleotide (5′TGGGAG3′, R-95288), Koizumi, M. et al. Bioorganic & Medicinal Chemistry, 1997, 5, 2235, bearing a 3,4-dibenzyloxybenzyl (3,4-DBB) group at the 5′-end and a 2-hydroxyethylphosphate at the 3′-end, has high anti-HIV-1 activity and the least cytotoxicity in vitro and in vivo. In order to synthesize more potent hexadeoxyribonucleotides, we substituted phosphodiester (PO) bonds in the 6-mer with the least phosphorothioate (PS), phosphoramidate (PN), or methylphosphonate (PMe) bonds. When more than two PN or PMe bonds were introduced into a 6-mer, the phosphate-modified 6-mers had weak or no anti-HIV-1 activity, in spite of quadruplex structure formation. However, when PS bonds were substituted for PO bonds, anti-HIV-1 activity of their 6-mers did not dramatically decrease, compared with compounds substituted with PN or PMe bonds. The results suggest that the formation of a quadruplex structure is not always sufficient for anti-HIV-1 activity of the 6-mer, and that net negative charges derived from PO or PS bonds in the quadruplex are important for anti-HIV-1 activity. Moreover, among various phosphate-modified ODNs, we found that the anti-HIV-1 activity of ODN PS7 with only one PS bond was the same as that of R-95288, both having a high stability in human plasma.</div>
<div type="abstract">Graphicgr1 </div>
</front>
</TEI>
</ISTEX>
<PubMed><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Biologically active oligodeoxyribonucleotides. Part 11: The least phosphate-modification of quadruplex-forming hexadeoxyribonucleotide TGGGAG, bearing 3-and 5-end-modification, with anti-HIV-1 activity.</title>
<author><name sortKey="Koizumi, M" sort="Koizumi, M" uniqKey="Koizumi M" first="M" last="Koizumi">M. Koizumi</name>
<affiliation wicri:level="3"><nlm:affiliation>Exploratory Chemistry Research Lab., Sankyo Co., Ltd, Tokyo, Japan. koizum@shina.sankyo.co.jp</nlm:affiliation>
<country xml:lang="fr">Japon</country>
<wicri:regionArea>Exploratory Chemistry Research Lab., Sankyo Co., Ltd, Tokyo</wicri:regionArea>
<placeName><settlement type="city">Tokyo</settlement>
<region type="région">Région de Kantō</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Koga, R" sort="Koga, R" uniqKey="Koga R" first="R" last="Koga">R. Koga</name>
</author>
<author><name sortKey="Hotoda, H" sort="Hotoda, H" uniqKey="Hotoda H" first="H" last="Hotoda">H. Hotoda</name>
</author>
<author><name sortKey="Ohmine, T" sort="Ohmine, T" uniqKey="Ohmine T" first="T" last="Ohmine">T. Ohmine</name>
</author>
<author><name sortKey="Furukawa, H" sort="Furukawa, H" uniqKey="Furukawa H" first="H" last="Furukawa">H. Furukawa</name>
</author>
<author><name sortKey="Agatsuma, T" sort="Agatsuma, T" uniqKey="Agatsuma T" first="T" last="Agatsuma">T. Agatsuma</name>
</author>
<author><name sortKey="Nishigaki, T" sort="Nishigaki, T" uniqKey="Nishigaki T" first="T" last="Nishigaki">T. Nishigaki</name>
</author>
<author><name sortKey="Abe, K" sort="Abe, K" uniqKey="Abe K" first="K" last="Abe">K. Abe</name>
</author>
<author><name sortKey="Kosaka, T" sort="Kosaka, T" uniqKey="Kosaka T" first="T" last="Kosaka">T. Kosaka</name>
</author>
<author><name sortKey="Tsutsumi, S" sort="Tsutsumi, S" uniqKey="Tsutsumi S" first="S" last="Tsutsumi">S. Tsutsumi</name>
</author>
<author><name sortKey="Sone, J" sort="Sone, J" uniqKey="Sone J" first="J" last="Sone">J. Sone</name>
</author>
<author><name sortKey="Kaneko, M" sort="Kaneko, M" uniqKey="Kaneko M" first="M" last="Kaneko">M. Kaneko</name>
</author>
<author><name sortKey="Kimura, S" sort="Kimura, S" uniqKey="Kimura S" first="S" last="Kimura">S. Kimura</name>
</author>
<author><name sortKey="Shimada, K" sort="Shimada, K" uniqKey="Shimada K" first="K" last="Shimada">K. Shimada</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="1998">1998</date>
<idno type="RBID">pubmed:9925303</idno>
<idno type="pmid">9925303</idno>
<idno type="doi">10.1016/s0968-0896(98)80021-7</idno>
<idno type="wicri:Area/PubMed/Corpus">002649</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">002649</idno>
<idno type="wicri:Area/PubMed/Curation">002649</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">002649</idno>
<idno type="wicri:Area/PubMed/Checkpoint">002553</idno>
<idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">002553</idno>
<idno type="wicri:Area/Ncbi/Merge">002B56</idno>
<idno type="wicri:Area/Ncbi/Curation">002B56</idno>
<idno type="wicri:Area/Ncbi/Checkpoint">002B56</idno>
<idno type="wicri:doubleKey">0968-0896:1998:Koizumi M:biologically:active:oligodeoxyribonucleotides</idno>
<idno type="wicri:Area/Main/Merge">003A67</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">Biologically active oligodeoxyribonucleotides. Part 11: The least phosphate-modification of quadruplex-forming hexadeoxyribonucleotide TGGGAG, bearing 3-and 5-end-modification, with anti-HIV-1 activity.</title>
<author><name sortKey="Koizumi, M" sort="Koizumi, M" uniqKey="Koizumi M" first="M" last="Koizumi">M. Koizumi</name>
<affiliation wicri:level="3"><nlm:affiliation>Exploratory Chemistry Research Lab., Sankyo Co., Ltd, Tokyo, Japan. koizum@shina.sankyo.co.jp</nlm:affiliation>
<country xml:lang="fr">Japon</country>
<wicri:regionArea>Exploratory Chemistry Research Lab., Sankyo Co., Ltd, Tokyo</wicri:regionArea>
<placeName><settlement type="city">Tokyo</settlement>
<region type="région">Région de Kantō</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Koga, R" sort="Koga, R" uniqKey="Koga R" first="R" last="Koga">R. Koga</name>
</author>
<author><name sortKey="Hotoda, H" sort="Hotoda, H" uniqKey="Hotoda H" first="H" last="Hotoda">H. Hotoda</name>
</author>
<author><name sortKey="Ohmine, T" sort="Ohmine, T" uniqKey="Ohmine T" first="T" last="Ohmine">T. Ohmine</name>
</author>
<author><name sortKey="Furukawa, H" sort="Furukawa, H" uniqKey="Furukawa H" first="H" last="Furukawa">H. Furukawa</name>
</author>
<author><name sortKey="Agatsuma, T" sort="Agatsuma, T" uniqKey="Agatsuma T" first="T" last="Agatsuma">T. Agatsuma</name>
</author>
<author><name sortKey="Nishigaki, T" sort="Nishigaki, T" uniqKey="Nishigaki T" first="T" last="Nishigaki">T. Nishigaki</name>
</author>
<author><name sortKey="Abe, K" sort="Abe, K" uniqKey="Abe K" first="K" last="Abe">K. Abe</name>
</author>
<author><name sortKey="Kosaka, T" sort="Kosaka, T" uniqKey="Kosaka T" first="T" last="Kosaka">T. Kosaka</name>
</author>
<author><name sortKey="Tsutsumi, S" sort="Tsutsumi, S" uniqKey="Tsutsumi S" first="S" last="Tsutsumi">S. Tsutsumi</name>
</author>
<author><name sortKey="Sone, J" sort="Sone, J" uniqKey="Sone J" first="J" last="Sone">J. Sone</name>
</author>
<author><name sortKey="Kaneko, M" sort="Kaneko, M" uniqKey="Kaneko M" first="M" last="Kaneko">M. Kaneko</name>
</author>
<author><name sortKey="Kimura, S" sort="Kimura, S" uniqKey="Kimura S" first="S" last="Kimura">S. Kimura</name>
</author>
<author><name sortKey="Shimada, K" sort="Shimada, K" uniqKey="Shimada K" first="K" last="Shimada">K. Shimada</name>
</author>
</analytic>
<series><title level="j">Bioorganic & medicinal chemistry</title>
<idno type="ISSN">0968-0896</idno>
<imprint><date when="1998" type="published">1998</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Anti-HIV Agents (blood)</term>
<term>Anti-HIV Agents (chemical synthesis)</term>
<term>Anti-HIV Agents (chemistry)</term>
<term>Anti-HIV Agents (pharmacology)</term>
<term>Base Sequence</term>
<term>Benzyl Compounds</term>
<term>Cell Survival (drug effects)</term>
<term>Circular Dichroism</term>
<term>Drug Design</term>
<term>Drug Stability</term>
<term>HIV-1 (drug effects)</term>
<term>Humans</term>
<term>Models, Molecular</term>
<term>Molecular Structure</term>
<term>Nucleic Acid Conformation</term>
<term>Oligodeoxyribonucleotides (blood)</term>
<term>Oligodeoxyribonucleotides (chemical synthesis)</term>
<term>Oligodeoxyribonucleotides (chemistry)</term>
<term>Oligodeoxyribonucleotides (pharmacology)</term>
<term>Structure-Activity Relationship</term>
</keywords>
<keywords scheme="KwdFr" xml:lang="fr"><term>Agents antiVIH ()</term>
<term>Agents antiVIH (pharmacologie)</term>
<term>Agents antiVIH (sang)</term>
<term>Agents antiVIH (synthèse chimique)</term>
<term>Composés benzyliques</term>
<term>Conception de médicament</term>
<term>Conformation d'acide nucléique</term>
<term>Dichroïsme circulaire</term>
<term>Humains</term>
<term>Modèles moléculaires</term>
<term>Oligodésoxyribonucléotides ()</term>
<term>Oligodésoxyribonucléotides (pharmacologie)</term>
<term>Oligodésoxyribonucléotides (sang)</term>
<term>Oligodésoxyribonucléotides (synthèse chimique)</term>
<term>Relation structure-activité</term>
<term>Stabilité de médicament</term>
<term>Structure moléculaire</term>
<term>Survie cellulaire ()</term>
<term>Séquence nucléotidique</term>
<term>VIH-1 (Virus de l'Immunodéficience Humaine de type 1) ()</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="blood" xml:lang="en"><term>Anti-HIV Agents</term>
<term>Oligodeoxyribonucleotides</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="chemical synthesis" xml:lang="en"><term>Anti-HIV Agents</term>
<term>Oligodeoxyribonucleotides</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="chemistry" xml:lang="en"><term>Anti-HIV Agents</term>
<term>Oligodeoxyribonucleotides</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="pharmacology" xml:lang="en"><term>Anti-HIV Agents</term>
<term>Oligodeoxyribonucleotides</term>
</keywords>
<keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Cell Survival</term>
<term>HIV-1</term>
</keywords>
<keywords scheme="MESH" qualifier="pharmacologie" xml:lang="fr"><term>Agents antiVIH</term>
<term>Oligodésoxyribonucléotides</term>
</keywords>
<keywords scheme="MESH" qualifier="sang" xml:lang="fr"><term>Agents antiVIH</term>
<term>Oligodésoxyribonucléotides</term>
</keywords>
<keywords scheme="MESH" qualifier="synthèse chimique" xml:lang="fr"><term>Agents antiVIH</term>
<term>Oligodésoxyribonucléotides</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Base Sequence</term>
<term>Benzyl Compounds</term>
<term>Circular Dichroism</term>
<term>Drug Design</term>
<term>Drug Stability</term>
<term>Humans</term>
<term>Models, Molecular</term>
<term>Molecular Structure</term>
<term>Nucleic Acid Conformation</term>
<term>Structure-Activity Relationship</term>
</keywords>
<keywords scheme="MESH" xml:lang="fr"><term>Agents antiVIH</term>
<term>Composés benzyliques</term>
<term>Conception de médicament</term>
<term>Conformation d'acide nucléique</term>
<term>Dichroïsme circulaire</term>
<term>Humains</term>
<term>Modèles moléculaires</term>
<term>Oligodésoxyribonucléotides</term>
<term>Relation structure-activité</term>
<term>Stabilité de médicament</term>
<term>Structure moléculaire</term>
<term>Survie cellulaire</term>
<term>Séquence nucléotidique</term>
<term>VIH-1 (Virus de l'Immunodéficience Humaine de type 1)</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">We have found that a hexadeoxyribonucleotide (5'TGGGAG3', R-95288), Koizumi, M. et al. Bioorganic & Medicinal Chemistry, 1997, 5, 2235, bearing a 3,4-dibenzyloxybenzyl (3,4-DBB) group at the 5'-end and a 2-hydroxyethylphosphate at the 3'-end, has high anti-HIV-1 activity and the least cytotoxicity in vitro and in vivo. In order to synthesize more potent hexadeoxyribonucleotides, we substituted phosphodiester (P-O) bonds in the 6-mer with the least phosphorothioate (P-S), phosphoramidate (P-N), or methylphosphonate (P-Me) bonds. When more than two P-N or P-Me bonds were introduced into a 6-mer, the phosphate-modified 6-mers had weak or no anti-HIV- activity, in spite of quadruplex structure formation. However, when P-S bonds were substituted for P-O bonds, anti-HIV-1 activity of their 6-mers did not dramatically decrease, compared with compounds substituted with P-N or P-Me bonds. The results suggest that the formation of a quadruplex structure is not always sufficient for anti-HIV-1 activity of the 6-mer, and that net negative charges derived from P-O or P-S bonds in the quadruplex are important for anti-HIV-1 activity. Moreover, among various phosphate-modified ODNs, we found that the anti-HIV-1 activity of ODN PS7 with only one P-S bond was the same as that of R-95288, both having a high stability in human plasma.</div>
</front>
</TEI>
</PubMed>
</double>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Sante/explor/MersV1/Data/Main/Curation

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 003A89 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/Main/Curation/biblio.hfd -nk 003A89 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Sante
   |area=    MersV1
   |flux=    Main
   |étape=   Curation
   |type=    RBID
   |clé=     ISTEX:AFC9863E4C7F650ECA44ED1DCE49EE59F9DF469E
   |texte=   Biologically active oligodeoxyribonucleotides. Part 11: The least phosphate-modification of quadruplex-forming hexadeoxyribonucleotide TGGGAG, bearing 3′- and 5′-end-modification, with anti-HIV-1 activity
}}

This area was generated with Dilib version V0.6.33.
Data generation: Mon Apr 20 23:26:43 2020. Site generation: Sat Mar 27 09:06:09 2021

	Serveur d'exploration MERS
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Serveur d'exploration MERS

Biologically active oligodeoxyribonucleotides. Part 11: The least phosphate-modification of quadruplex-forming hexadeoxyribonucleotide TGGGAG, bearing 3′- and 5′-end-modification, with anti-HIV-1 activity

Biologically active oligodeoxyribonucleotides. Part 11: The least phosphate-modification of quadruplex-forming hexadeoxyribonucleotide TGGGAG, bearing 3′- and 5′-end-modification, with anti-HIV-1 activity

Source :

Descripteurs français

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri